Asset Details
Do you wish to reserve the book?
Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma
Do you wish to request the book?
Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma
2020
Overview
Background
Adult T-cell leukemia-lymphoma (ATL) is an aggressive mature lymphoid proliferation associated with poor prognosis. Standard of care includes chemotherapy and/or the combination of zidovudine and interferon-alpha. However, most patients experience relapse less than 6 months after diagnosis. Allogeneic stem cell transplantation is the only curative treatment, but is only feasible in a minority of cases. We previously showed in a mouse model that Arsenic trioxide (As
2
O
3
) targets ATL leukemia initiating cells.
Results
As
2
O
3
consolidation was given in 9 patients with ATL (lymphoma n = 4; acute n = 2; and indolent n = 3), who were in complete (n = 4) and partial (n = 3) remission, in stable (n = 1) and in progressive (n = 1) disease. Patients received up to 8 weeks of As
2
O
3
at the dose of 0.15 mg/kg/day intravenously in combination with zidovudine and interferon-alpha. One patient in progression died rapidly. Of the remaining eight patients, three with indolent ATL subtype showed overall survivals of 48, 53 and 97 months, and duration of response to As
2
O
3
of 22, 25 and 73 months. The other 5 patients with aggressive ATL subtype had median OS of 36 months and a median duration of response of 10 months. Side effects were mostly hematological and cutaneous (one grade 3) and reversible with dose reduction of AZT/IFN and/or As
2
O
3
discontinuation. The virus integration analysis revealed the regression of the predominant malignant clone in one patient with a chronic subtype.
Conclusion
These results suggest that consolidation with As
2
O
3
could be an option for patients with ATL in response after induction therapy and who are not eligible for allogeneic stem cell transplantation.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Adult
/ Analysis
/ Arsenic
/ Arsenic Trioxide - administration & dosage
/ Arsenic Trioxide - therapeutic use
/ ATL
/ Biological response modifiers
/ Biomedical and Life Sciences
/ Cancer
/ Cloning
/ DNA
/ Female
/ HTLV-1: a re-emerging human pathogen
/ Human T-lymphotropic virus 1 - drug effects
/ Humans
/ Interferon-alpha - therapeutic use
/ Leukemia
/ Leukemia-Lymphoma, Adult T-Cell - drug therapy
/ Lymphoma
/ Male
/ Patients
/ T cells
/ Vaccine
/ Virology
